Aardvark Therapeutics' stock dropped 32% following the FDA's clinical hold on its Prader-Willi Syndrome drug, ARD-101, after serious safety concerns led to a voluntary trial pause. This follows an earlier 56% drop when the company stopped its Phase 3 trial due to safety risks. The situation has triggered an investigation into whether Aardvark misled investors about the drug's safety and FDA communications. Investors with losses are encouraged to participate in the ongoing legal inquiry.
Agios Pharmaceuticals saw its stock surge after H.C. Wainwright raised the price target to $55, implying a 67% upside. The company reported Q2 2026 revenues of $44.75 million, nearly doubling estimates, driven by strong sales of its drug mitapivat (P...
RBC Capital increased its price target for Intesa Sanpaolo to €7.25 from €7.00 and maintained an Outperform rating, citing the bank's strong financial performance. Intesa Sanpaolo reported Q2 net profit of €2.79 billion, beating expectations, and now...
Peapack-Gladstone Financial Corporation announced a quarterly cash dividend of $0.05 per share, payable on August 27, 2026, to shareholders of record as of August 13, 2026. The company is a New Jersey-based bank holding firm with $8 billion in assets...
Inno Holdings Inc. announced that its common stock will resume trading on The Nasdaq Capital Market starting July 31, 2026, after a trading halt was imposed on June 12, 2026, due to unusual trading activities. The company stated it is unaware of any ...
iBUYPOWER, known for gaming PCs, has expanded into professional workstations with its new iBUYPOWER PRO line, targeting creative and technical professionals. These systems feature high-end Intel and AMD CPUs, NVIDIA and AMD GPUs, and come with a new ...
